Most BMETs occur in patients with estrogen receptor-positive (ER+) tumors, both due to the higher prevalence of this tumor subtype, including among those with metastatic disease (70%), as well as the higher prevalence of BMETs in ER+ (vs. ER-) metastatic disease [5,6,7,8]. The gene discussed is ESR1; the disease is neoplasm.